StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Reimbursement liability to R&D funding partners, current by Quarter

Reimbursement liability to R&D funding partners, current ($M) ($M)

QuarterlyAnnual

Moderna Reimbursement liability to R&D funding partners, current: $58M in Q2 2026, down 50.8% from a year earlier.

Latest, Q2 2026
58
Period ended Jun 30, 2026
Change on a year earlier
-50.8%
118 in Q2 2025
History
9 quarters
Since Q4 2023
Sources
8
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Collaboration & Funding Agreements Note.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReimbursement liability to R&D funding partners, current ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202658-50.8%Form 10-Q (filed 2026-07-31) ↗
Q1 2026Mar 31, 2026111-38.0%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 202584-18.4%Form 10-Q (filed 2026-07-31) ↗
Q3 2025Sep 30, 20250–Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025118–Form 10-Q (filed 2025-08-01) ↗
Q1 2025Mar 31, 2025179+50.4%Form 10-Q (filed 2025-05-01) ↗
Q4 2024Dec 31, 2024103–Form 10-K (filed 2026-02-20) ↗
Q1 2024Mar 31, 2024119–Form 10-Q (filed 2024-05-02) ↗
Q4 2023Dec 31, 20230–Form 10-K (filed 2025-02-21) ↗

Cite this data

StockData. (2026). Moderna Reimbursement liability to R&D funding partners, current ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/reimb-liab-cur

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.